H&E Diagnosis & Classification of Colon Cancer: An Overview

From Specimen to Diagnosis

The diagnostic journey for colon cancer begins with tissue. Whether the material arrives as a small endoscopic biopsy, a polypectomy fragment, or a full surgical resection of bowel, the same first principle applies: malignancy in the colon is a histological diagnosis, confirmed by a pathologist examining stained sections under the microscope. The workhorse stain is hematoxylin and eosin (H&E), which renders nuclei blue-purple and cytoplasm and stroma in shades of pink. Against this familiar palette, the pathologist asks a sequence of questions: Is this neoplastic? Is it invasive? What lineage does it belong to? And how aggressive does it appear?

In colorectal pathology, morphology is comparatively straightforward — most tumors are gland-forming adenocarcinomas — but the meaningful action increasingly lies along a molecular axis layered on top of the H&E picture [1]. For this reason, modern reporting integrates what the eye sees with immunohistochemistry (IHC) and molecular testing, especially mismatch-repair (MMR) status. The slide tells you the category; the molecular workup often tells you what that category means for prognosis.

The H&E Picture (Synthesized Morphology)

The defining feature of conventional colorectal carcinoma is glandular differentiation — malignant epithelial cells forming gland-like (tubular) structures — accompanied by desmoplastic invasion, a reactive fibrous stromal response that signals true invasion through the basement membrane rather than a contained, non-invasive lesion [1]. Recognizing invasion is what separates carcinoma from high-grade dysplasia confined to the mucosa.

Beyond this baseline, the H&E appearance varies in ways that define recognized subtypes. Some tumors flood the field with pools of extracellular mucin; others are dominated by cells whose cytoplasm is so distended by mucin that the nucleus is pushed to the periphery, creating the characteristic signet-ring morphology. A minority of tumors abandon glandular architecture entirely and grow as organoid nests or sheets with neuroendocrine features. Each of these patterns maps onto a distinct diagnostic category.

When morphology alone is ambiguous — for instance, distinguishing a colonic primary from a metastasis — IHC clarifies lineage. The typical colorectal immunoprofile is CK20-positive, CDX2-positive, SATB2-positive, and CK7-negative [1]. This signature is especially valuable for signet-ring tumors, where a colonic origin must be distinguished from metastatic gastric or lobular breast carcinoma that can look nearly identical on H&E.

The Major Categories

Colorectal tumors fall into a small number of named entities, each warranting its own detailed treatment.

Adenocarcinoma, not otherwise specified (NOS) is the default and by far the most common category — gland-forming malignant epithelium with desmoplastic invasion [1]. It arises predominantly through two molecular routes: the chromosomal-instability pathway (APC/KRAS/TP53) or the serrated pathway associated with microsatellite instability (MSI) and CpG-island methylation (CIMP) [1]. Most other entities are best understood as variants of this default.

Mucinous adenocarcinoma is defined when more than 50% of the tumor is composed of extracellular mucin pools [1]. It is enriched for MSI-high and BRAF/CIMP biology and tends to occur in right-sided tumors — an early illustration of how morphology, location, and molecular pathway travel together.

Signet-ring cell carcinoma requires that more than 50% of the tumor consist of signet-ring cells with intracytoplasmic mucin displacing the nucleus [1]. This is an adverse morphology, considered high-grade by definition. IHC can be variable here — CDX2 may be lost and E-cadherin reduced — which makes excluding metastatic mimics by clinical and immunohistochemical context essential.

Neuroendocrine neoplasms form a separate lineage altogether, not adenocarcinoma variants. This family spans well-differentiated neuroendocrine tumors (NET), graded G1 to G3; poorly differentiated neuroendocrine carcinoma (NEC); and mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN), in which each component constitutes at least 30% of the tumor [1]. These are recognized by neuroendocrine morphology together with marker expression — synaptophysin, chromogranin, and INSM1 — with Ki-67 used to assign grade [1]. NEC shares TP53/RB1 alterations with high-grade neuroendocrine carcinomas elsewhere in the body.

How Grading and Staging Work

Grading conventional adenocarcinoma uses a two-tier system based on gland formation: low-grade tumors (well to moderately differentiated) form glands in at least 50% of the tumor, while high-grade tumors (poorly differentiated) form glands in less than 50% [1]. This is a deliberately simplified scheme compared with older multi-tier grades.

The crucial caveat — and a recurring theme in colorectal pathology — is that morphology and biology can diverge. MSI-high tumors frequently appear high-grade by gland-formation criteria yet behave more favorably [1]. The evidence suggests that MMR status reframes prognosis independent of the H&E grade, which is why grade is no longer interpreted in isolation. Mucinous tumors make this explicit: an MSI-high mucinous carcinoma is treated as low-grade, whereas a microsatellite-stable (MSS) mucinous carcinoma is treated as high-grade [1]. Grade, in other words, has become a function of molecular context rather than appearance alone.

Neuroendocrine neoplasms follow a parallel but separate grading logic. Well-differentiated NETs are graded G1/G2/G3 by Ki-67 proliferation index and mitotic count — the same axis used across gastrointestinal and pancreatic NETs — while NEC is high-grade by definition and MiNEN is classified by the proportions of its components [1].

Staging, distinct from grading, describes anatomical extent — depth of invasion through the bowel wall, lymph node involvement, and distant spread — and is assessed largely on resection specimens. Grade and stage are complementary: one captures how the tumor looks and behaves intrinsically, the other captures how far it has spread.

Why Classification Matters

Classification is not an academic exercise. The named category determines the differential diagnosis (a signet-ring pattern demands exclusion of metastatic mimics), the prognostic expectation (signet-ring and MSS mucinous tumors carry adverse implications; MSI-high tumors are reframed favorably), and — critically — eligibility for entire drug classes. MMR/MSI status, layered onto the morphological diagnosis, identifies tumors of a biology associated with immune-checkpoint-inhibitor eligibility. None of this is patient-directed advice; it is the logic by which a diagnosis opens or closes therapeutic doors at the level of drug classes, decisions that belong to the treating clinical team.

What's Current

Under the WHO Classification of Digestive System Tumours, 5th edition (2019), colorectal classification has become molecular-forward [1]. Histology remains comparatively simple, but the framework now insists that MMR/MSI status be integrated with morphology — most visibly in the rule that grade for mucinous carcinoma is read through MMR status rather than appearance [1]. The recognition that sidedness (right versus left) correlates with molecular pathway further embeds biology into routine interpretation. The neuroendocrine family was also formalized with the unified NET/NEC/MiNEN terminology shared across digestive organs [1]. The evidence in this area is fast-moving; grading specifics and the precise integration of molecular data continue to evolve, and readers should verify current criteria against the latest standards.

---

References

1. WHO Classification of Tumours Editorial Board. Digestive System Tumours, 5th ed. Lyon: IARC; 2019. ISBN 978-92-832-4499-8.